NCT01809808 2025-08-26
A Prospective Study of Outcome After Therapy for Acromegaly
Columbia University
Completed
Clinical Trials
16 trialsNCT06253897 2024-12-24
BackSOM
Ipsen
Completed
NCT01794793 2024-10-01
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP
Phase 4 Completed
NCT00001981 2020-11-27
The Treatment and Natural History of Acromegaly
National Institutes of Health Clinical Center (CC)
Completed
NCT01673646 2019-09-16
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
Novartis
Phase 2 Completed
NCT01840449 2019-01-14
SOPRANo
Ipsen
Completed
NCT01504399 2018-08-22
Rhinological Outcomes in Endonasal Pituitary Surgery
St. Joseph's Hospital and Medical Center, Phoenix
Completed
NCT02299089 2017-12-15
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
Camurus AB
Phase 2 Completed
NCT00376064 2017-03-06
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
Novartis
Phase 4 Completed
NCT00171886 2017-02-24
Octreotide Efficacy and Safety in First-line Acromegalic Patients
Novartis
Phase 4 Completed
NCT01568359 2014-12-05
Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors
Emory University
Completed
NCT00001860 2008-03-04
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00017927 2008-03-04
A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT00627796 2008-03-03
ATG1line
Federico II University
Phase 4 Completed
NCT00616408 2008-02-15
Prediction of Tumor Shrinkage in Acromegaly
Federico II University
Completed
NCT00461149 2007-04-17
HDacro
Federico II University
Phase 4 Completed